[Interrelationships between serum and secretory antibodies in immunization with live influenza vaccine]. 1975

Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva

A study was made of the accumulation of antibodies in the blood serum and the secretions of the respiratory tracts of persons immunized with the living influenza vaccine. The duration of inductive phase and the dynamics of the antibody accumulation in the secretions occurred irrespective of their initial level in the blood sera, this pointing to the autonomic character of the local immunity system. On the other hand the functional condition of the system of local immunity influenced the intensity of the antibody formation in the system of the general immunity. If before the immunization the antibody titre in the secretions were 1:4 and greater, the antibody accumulation in the blood sera took place less intensively. An analogous phenomenon was also observed when the antibodies were absent in the secretions before the immunization, but their formation took place as soon as the first week after it. The mechanism of this peculiar "competition for the antigen" of the systems of local and general immunity consisted in the neutralization of the influenza virus in the area of the porta of infection.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007071 Immunoglobulin A, Secretory The principle immunoglobulin in exocrine secretions such as milk, respiratory and intestinal mucin, saliva and tears. The complete molecule (around 400 kD) is composed of two four-chain units of IMMUNOGLOBULIN A, one SECRETORY COMPONENT and one J chain (IMMUNOGLOBULIN J-CHAINS). Colostral IgA,IgA, Exocrine,IgA, Secretory,SIgA,Secretory IgA,Secretory Immunoglobulin A,Exocrine IgA,IgA, Colostral
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D009296 Nasal Cavity The proximal portion of the respiratory passages on either side of the NASAL SEPTUM. Nasal cavities, extending from the nares to the NASOPHARYNX, are lined with ciliated NASAL MUCOSA. Nasal Cavities,Cavities, Nasal,Cavity, Nasal
D009297 Nasal Mucosa The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells. Nasal Epithelium,Schneiderian Membrane,Epithelium, Nasal,Membrane, Schneiderian,Mucosa, Nasal

Related Publications

Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
January 1979, Trudy Instituta imeni Pastera,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
January 1988, Trudy Instituta imeni Pastera,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
May 1977, The Journal of infectious diseases,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
August 1976, The Journal of allergy and clinical immunology,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
November 1968, Casopis lekaru ceskych,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
January 1983, Voprosy virusologii,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
May 1972, Vrachebnoe delo,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
October 1991, Vaccine,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
January 2011, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Ia S Shvartsman, and V A Krylov, and E N Agranovskaia, and A I Mal'tseva
April 2013, Disaster medicine and public health preparedness,
Copied contents to your clipboard!